Why India needs a smarter healthcare margin policy

India needs a more nuanced approach to healthcare pricing, according to experts. The recent debate over Maximum Retail Price (MRP) reveals a lack of understanding regarding the complexities of cost structures. While hospitals acknowledge that the gap between procurement and billing costs includes storage, sterility maintenance, and availability, patients rightfully question why "maximum" prices often become the norm.

The Minimum Retail Price (MRP) was initially designed as a ceiling to protect consumers, but it can also obscure how prices are constructed. This can make it difficult for patients to compare options in emergencies when choice disappears, potentially leading to inflated charges. Price controls may help reduce patient burden, as demonstrated by the National Pharmaceutical Pricing Authority's 2019 intervention that saved patients 200 crore annually by rationalizing margins for non-scheduled cancer medicines.

However, the solution should not be a one-size-fits-all approach. Rather, India should develop a differential profit and margin strategy that considers the value each product brings. Routine, high-volume products should have modest, transparent margins, while innovative therapies and rare disease treatments should command higher returns to compensate for the risks and investments involved.

Companies that invest heavily in research and development should be rewarded fairly, but the premium should be tied to genuine clinical value, not simply new branding or marketing. A balanced pricing policy should protect consumers from overcharging while also rewarding innovative companies that develop life-changing treatments.

This can be achieved through a transparent pricing system with robust oversight, evidence-based decision-making, and enforceable agreements to ensure patients receive fair access to essential healthcare products.